CRISPR, ViaCyte Team Up to Develop Stem Cell-Based Diabetes Therapy

ViaCyte’s attempts to develop a stem cell therapy for diabetes have been stymied by the immune system, which recognizes the implanted cells as foreign. Meanwhile, CRISPR Therapeutics has found success in gene-editing cells so that the cells avoid such immune responses.